The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells

Fra-1 is aberrantly expressed in a large number of cancer cells and tissues, and emerging evidence suggests an important role for this Fos family protein in both oncogenesis and the progression or maintenance of many tumour types. Here, we show that the concentration of Fra-1 is high in invasive oestrogen receptor (ER)-negative (ER−) breast cancer cell lines, regardless of their Ras pathway status. All of the ER− cells express high levels of activated PKCθ, and the inhibition of PKCθ activity using RNA interference or the expression of a dominant-negative mutant results in a dramatic reduction in Fra-1 abundance. Conversely, the ectopic expression of constitutively active PKCθ leads to Fra-1 phosphorylation and accumulation in poorly invasive ER+ cells. This accumulation is due to the stabilisation of the Fra-1 protein through PKCθ signalling, whereas other members of the PKC family are ineffective. Both Ste20-related proline-alanine-rich kinase (SPAK) and ERK1/2, whose activities are upregulated by PKCθ, participate in PKCθ-driven Fra-1 stabilisation. Interestingly, their relative contributions appear to be different depending on the cell line studied. ERK1/2 signalling has a major role in ER− MDA-MB-231 cells, whereas Fra-1 accumulation occurs mainly through SPAK signalling in ER− BT549 cells. Fra-1 mutational analysis shows that the phosphorylation of S265, T223 and T230 is critical for PKCθ-driven Fra-1 stabilisation. Phosphorylation of the protein was confirmed using specific antisera against Fra-1 phosphorylated on T223 or S265. In addition, Fra-1 participates in PKCθ-induced cell invasion and is necessary for PKCθ-induced cell migration. In summary, we identified PKCθ signalling as an important regulator of Fra-1 accumulation in ER− breast cancer cells. Moreover, our results suggest that PKCθ could participate in progression of some breast cancers and could be a new therapeutic target.

[1]  Ole Winther,et al.  RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. , 2009, Molecular cell.

[2]  S. Manicassamy,et al.  Selective function of PKC-theta in T cells. , 2006, Cellular & molecular immunology.

[3]  M. Schuermann,et al.  Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins , 1998, Oncogene.

[4]  W. Debinski,et al.  Fos-Related Antigen 1 Modulates Malignant Features of Glioma Cells , 2005, Molecular Cancer Research.

[5]  V. Berezin,et al.  Fra-1 Induces Morphological Transformation and Increases In Vitro Invasiveness and Motility of Epithelioid Adenocarcinoma Cells , 1998, Molecular and Cellular Biology.

[6]  E. Sahai,et al.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. , 2003, Cancer cell.

[7]  G. Sonenshein,et al.  PKCθ promotes c-Rel–driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis , 2007 .

[8]  E. Delpire,et al.  Cation Chloride Cotransporters Interact with the Stress-related Kinases Ste20-related Proline-Alanine-rich Kinase (SPAK) and Oxidative Stress Response 1 (OSR1)* , 2002, The Journal of Biological Chemistry.

[9]  K. Belguise,et al.  FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells , 2005, Oncogene.

[10]  Frank McCormick,et al.  The molecular pathology of cancer , 2010, Nature Reviews Clinical Oncology.

[11]  P. Verde,et al.  Deciphering AP-1 Function in Tumorigenesis: Fra-ternizing on Target Promoters , 2007, Cell cycle.

[12]  Jorma Isola,et al.  3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. , 2009, Cancer research.

[13]  N. Colburn,et al.  Fra-1 a target for cancer prevention or intervention. , 2006, Gene.

[14]  J. Blenis,et al.  ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. , 2010, Molecular cell.

[15]  R. Vita,et al.  SPAK kinase is a substrate and target of PKCθ in T‐cell receptor‐induced AP‐1 activation pathway , 2004, The EMBO journal.

[16]  M. Talpaz,et al.  The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation. , 2006, Biochemical and biophysical research communications.

[17]  M. Brentani,et al.  Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma , 2011, Histopathology.

[18]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[19]  A. Philips,et al.  FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. , 1998, Molecular endocrinology.

[20]  T. Tan,et al.  The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells , 2011, Nature Immunology.

[21]  R. Hipskind,et al.  Activation of cyclin D1 expression by the ERK5 cascade , 2003, Oncogene.

[22]  Sabine Riethdorf,et al.  FosB is Highly Expressed in Normal Mammary Epithelia, but Down-Regulated in Poorly Differentiated Breast Carcinomas , 2003, Breast Cancer Research and Treatment.

[23]  Mieke Schutte,et al.  Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.

[24]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[25]  G. Sonenshein,et al.  PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. , 2007, The Journal of clinical investigation.

[26]  S. Hurtley.  Time for a Pause , 2011, Science Signaling.

[27]  E. Campo,et al.  Protein Kinase C θ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias , 2004, Clinical Cancer Research.

[28]  Zefei Jiang,et al.  An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy , 2006, BMC Cancer.

[29]  M. Yaniv,et al.  Transformation by ras modifies AP1 composition and activity , 1997, Oncogene.

[30]  H. Ni,et al.  Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages , 2010, Cell Research.

[31]  A. Altman,et al.  Protein kinase C theta (PKCθ) : A key player in T cell life and death , 2007 .

[32]  Shuang Huang,et al.  Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. , 2009, Cancer research.

[33]  M. Kopf,et al.  T-cell fate and function: PKC-theta and beyond. , 2008, Trends in immunology.

[34]  R. Hipskind,et al.  Ubiquitin-Independent Proteasomal Degradation of Fra-1 Is Antagonized by Erk1/2 Pathway-Mediated Phosphorylation of a Unique C-Terminal Destabilizer , 2007, Molecular and Cellular Biology.

[35]  Liliane A. T. Arnaldi,et al.  FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders , 2007, BMC Cancer.

[36]  A. Dhillon,et al.  Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL , 2012, Oncogene.

[37]  Ru-Fang Yeh,et al.  TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer , 2011, Science Signaling.

[38]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[39]  E. Mallon,et al.  Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression , 2010, British Journal of Cancer.

[40]  C. Marshall,et al.  Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells , 2003, Journal of Cell Science.

[41]  A. Altman,et al.  Protein kinase C theta (PKCtheta): a key player in T cell life and death. , 2007, Pharmacological research.

[42]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[43]  H. Grunicke,et al.  Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes , 1996, Molecular and cellular biology.

[44]  G. Sonenshein,et al.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2 , 2007, Nature Cell Biology.

[45]  E. Delpire,et al.  Genome-wide analysis of SPAK/OSR1 binding motifs. , 2007, Physiological genomics.

[46]  G. Viglietto,et al.  Neoplastic transformation of rat thyroid cells requires the junB and fra‐1 gene induction which is dependent on the HMGI‐C gene product , 1997, The EMBO journal.

[47]  A. Brunet,et al.  Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. , 1994, Oncogene.